Persistent genital chlamydial infection may lead to tubal factor infertility (TFI). Chlamydia trachomatis TroA and HtrA are proteins expressed during persistent chlamydial infection in vitro. We studied serum IgG antibody response against these proteins by EIA in women with TFI and in subfertile women without tubal pathology. Altogether, 22 of 258 subfertile women (8.5%) had TFI which was unilateral in 17 cases and bilateral in 5 cases. Overall, 55 (21.3%) of the 258 women had TroA and 39 (15.1%) had HtrA antibodies. Seropositivity to TroA and HtrA was more common among women with TFI than women with other causes for subfertility (45.5 vs. 19.1%, p = 0.004 for TroA; 36.4 vs. 13.1%, p = 0.004 for HtrA). Mean absorbance values and the prevalence of TroA and HtrA antibodies increased with increasing severity of TFI. On the basis of our results, TroA and HtrA serology has the potential to be further developed to a specific biomarker for C. trachomatis-related TFI.
Introduction
Chlamydia trachomatis is the causative pathogen of the most prevalent bacterial sexually transmitted infection worldwide [1] . The majority of infected women have uncomplicated lower genital tract infection, while some women develop persistent or ascending chlamydial infection [2] . This may lead to scarring of Fallopian tubes predisposing to tubal factor infertility (TFI) and ectopic pregnancy (EP). C. trachomatis IgG antibody test has been introduced as a screening test for TFI in subfertile women [3] , but the presence of serum chlamydial antibodies indicates only exposure to the pathogen and cannot discriminate past immunity from persistent infection. More accurate methods for TFI evaluation are needed.
In vitro studies have shown that under stressful growth conditions, C. trachomatis can transform into a persistent form characterized by incomplete developmental cycle and altered gene transcription profile [4] . TroA (YtgA) is a substrate binding protein in the iron transport system of C. trachomatis. The expression of TroA increases when the bacterium is cultured under iron starvation conditions [5] . High temperature requirement protein (HtrA) is a highly conserved serine protease and has an essential role during C. trachomatis replication [6] . HtrA concentration increases when C. trachomatis is cultivated in the presence of penicillin [7] . In our previous study, we concluded that TroA and HtrA could be potential biomarkers for ascending and repeated C. trachomatis infection [8] . The aim of our present study was to investigate the presence of serum IgG antibodies to C. trachomatis TroA and HtrA among subfertile women with TFI.
Materials and methods

Study population
Our study population consisted of 258 women referred for infertility to Helsinki University Hospital during July 2007-December 2010. Infertility work-up was performed according to the clinic's routine protocol after at least 1 year of unprotected intercourse. Tubal patency was evaluated either by hysterosalpingosonography (HSSG) or by laparoscopy (Fig. 1) . TFI was defined as an occlusion of at least one tube. Cases with EP before or during infertility evaluation (n = 11) were included in the unilateral TFI group. Subfertile women with another etiology for subfertility, such as ovulatory disorder (n = 69), endometriosis (n = 37), male factor infertility (n = 25), unexplained infertility (n = 96), or other sporadic cause (hormonal disorder, structural anomaly, or pelvic adhesions due to previous pelvic surgery; n = 9), served as the reference group. First-void urine or cervical swab specimen was collected for diagnosis of C. trachomatis by the nucleic acid amplification test (NAAT) [9] .
Serological methods
Serum samples for the serological analysis were collected at the first outpatient clinic visit and stored at − 20°C until analyzed. IgG antibody responses to the recombinant TroA and HtrA were analyzed by enzyme immune assay (EIA) as described in detail earlier [8] . The cutoff values were based on the absorbance values (mean + 2 SD) obtained using specimens of sexually inexperienced girls not exposed to C. trachomatis and were set as A 450nm 0.5. Sera were also studied by microimmunofluorescence test (MIF). MIF serology was performed using purified elementary bodies (EB) of C. trachomatis and Chlamydophila pneumoniae as antigen [10] . MIF titers were classified as high (≥ 128) or low (≤ 64).
Statistical methods
Chi-squared test was used for the analysis of categorical data. Continuous variables were compared by the MannWhitney U test as appropriate. Correlations between MIF titers and ranked EIA absorbance values were analyzed by Spearman's correlation coefficient and levels at ≤ 0.01 were considered statistically significant. All statistical analyses were performed by IBM SPSS Statistics 22.0 (IBM Corp., Armonk, NY) and STATA version 13 (StataCorp. Stata Statistical Software: Release 13. College Station, TX: StataCorp LP. 2013).
Results
The baseline characteristics
Altogether, 22 (8.5%) of the 258 subfertile women had TFI. Of those, bilateral tubal occlusion was found in five women and unilateral tubal occlusion in 17 women (Fig. 1) . At the time of serum sampling, none had positive C. trachomatis nucleic acid amplification test (NAAT) from the urogenital sample. The baseline characteristics by the presence of C. trachomatis TroA and HtrA IgG are presented in Table 1 (Fig. 2) .
Of the women with high MIF titers (≥ 128), 75.0% were TroA antibody positive and 58.3% were HtrA antibody Tubal status examined n=211:
HSSG (n=160) Laparoscopy (n=51) HSSG and laparoscopy (n=8)
SubferƟle women included in the cohort n=258
SubferƟle women recruited N=268
Tubal pathology n=35: Tubal occlusion (n=24) Ectopic pregnancy (n=11)
Tubal factor inferƟlity n= 22
Excluded n=10* Tubal status not examined n=47
Tubal occlusion caused by endometriosis or previous pelvic surgery n=13 
Discussion
We studied antibody responses against two C. trachomatis proteins, TroA and HtrA, expressed during persistent C. trachomatis infection, among subfertile women. Serum antibodies to TroA and HtrA were more common in women with TFI than in subfertile women with another cause for subfertility. Furthermore, seropositivity rates and the To the best of our knowledge, this is the first study on serum antibody responses against C. trachomatis TroA and HtrA in subfertile women. Our results are in line with a previous study by Stansfield et al. who suggested that HtrA could be used as a potential biomarker in distinguishing women with C. trachomatis sequelae (TFI, EP, and PID) from those with history of single infection or multiple uncomplicated infections [11] .
Microimmunofluorescence serology (MIF) has been considered the gold standard in the serological diagnosis of C. trachomatis, but the presence of antibodies does not distinguish past exposure and clearance of infection from persistent infection which increases the risk of TFI. In our study, a moderate correlation was found between TroA and HtrA antibody EIA absorbance levels and MIF C. trachomatis antibody titers. This is plausible, since TroA and HtrA antibody tests detect conditions for which serological marker or laboratory reference method is not available.
The patency of Fallopian tubes was mainly evaluated by HSSG in our study. The weaknesses of this method include the possibility of false-positive results because of tubal spasm. However, the sensitivity and specificity of HSSG is 0.95 and 0.93 compared to laparoscopy, which is considered the gold standard for diagnosing tubal pathology [12] . Moreover, HSSG allows the visualization of ovaries and uterine cavity [12] . Another limitation of our study was the low prevalence of TFI (8.5%). Due to the high screening activity, C. trachomatis infections are diagnosed and treated early before PID and associated TFI develop.
C. trachomatis TroA and HtrA serology has the potential to be used as a specific biomarker to predict C. trachomatisrelated tubal pathology. However, our results need to be confirmed in larger study populations. Furthermore, the development of TFI is multifactorial, and further studies on the natural history of C. trachomatis infection are needed.
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